Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...

Like base editing, prime editing offers a safer way to genome editing by relying on a nickase enzyme that “nicks” one DNA strand at a time, rather than cutting both simultaneously. Then, with the ...

Keith Gottesdiener, MD, former president and CEO of Prime Medicine Prime Medicine is eliminating 25% of its workforce—about 50 jobs—in a restructuring that includes the company pivoting its prime ...

Prime Medicine, Inc. (PRME) was able to release positive data in using its Prime Editing technology therapy PM359 to treat one patient with Chronic Granulomatous Disease [CGD]. The patient was noted ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific presentations. PRME's Prime Editing platform targets multi-billion-dollar markets ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...

Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359 New preclinical data highlighted ...